{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:38:17Z","timestamp":1792165097559,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11695-018-3249-1","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T13:10:56Z","timestamp":1523970656000},"page":"2113-2116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery"],"prefix":"10.1007","volume":"28","author":[{"given":"Renuca","family":"Modi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cawsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya M.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"issue":"8","key":"3249_CR1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","volume":"127","author":"CF Shaefer","year":"2015","unstructured":"Shaefer CF, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818\u201326.","journal-title":"Postgrad Med"},{"key":"3249_CR2","unstructured":"Novo Nordisk Canada Inc. Saxenda\u00ae Product Monograph. \nhttp:\/\/www.novonordisk.ca\/content\/dam\/Canada\/AFFILIATE\/www-novonordisk-ca\/OurProducts\/PDF\/Saxenda_PM_English.pdf\n\n. Published 2017 July 12. Accessed 10 December 2017."},{"issue":"2","key":"3249_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrgastro.2015.202","volume":"13","author":"RD Naik","year":"2016","unstructured":"Naik RD, Choksi YA, Vaezi MF. Consequences of bariatric surgery on oesophageal function in health and disease. Nat Rev Gastroenterol Hepatol. 2016;13(2):111\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"3249_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5056\/jnm.2011.17.2.189","volume":"17","author":"JW Seok","year":"2011","unstructured":"Seok JW. How to interpret gastric emptying scintigraphy. J Neurogastroenterol Motil. 2011;17(2):189\u201391.","journal-title":"J Neurogastroenterol Motil"},{"key":"3249_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11894-016-0534-9","volume":"18","author":"A Patel","year":"2016","unstructured":"Patel A, Gyawali CP. How to optimally apply impedance in the evaluation of esophageal dysmotility. Curr Gastroenterol Rep. 2016;18:60.","journal-title":"Curr Gastroenterol Rep"},{"issue":"Suppl 1","key":"3249_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1590\/S0102-6720201500S100012","volume":"28","author":"MS Assef","year":"2015","unstructured":"Assef MS, Melo TT, Araki O, et al. Evaluation of upper gastrointestinal endoscopy in patients undergoing bariatric surgery. Arq Bras Cir Dig. 2015;28(Suppl 1):39\u201342.","journal-title":"Arq Bras Cir Dig"},{"issue":"4","key":"3249_CR7","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1053\/gast.2003.50159","volume":"124","author":"T Piche","year":"2003","unstructured":"Piche T, Des varannes SB, Sacher-huvelin S, et al. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology. 2003;124(4):894\u2013902.","journal-title":"Gastroenterology"},{"issue":"6","key":"3249_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","volume":"38","author":"J Van Can","year":"2014","unstructured":"Van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obesity (2005). 2014;38(6):784\u201393.","journal-title":"Int J Obesity (2005)"},{"issue":"2","key":"3249_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","volume":"97","author":"M Horowitz","year":"2012","unstructured":"Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(2):258\u201366.","journal-title":"Diabetes Res Clin Pract"},{"key":"3249_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","volume":"43","author":"Y Nakatani","year":"2017","unstructured":"Nakatani Y, Maeda M, Matsumura M, et al. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017; [Epub ahead of print];43:430\u20137.","journal-title":"Diabetes Metab"},{"issue":"5","key":"3249_CR11","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/S0016-5085(17)30625-X","volume":"152","author":"D Khemani","year":"2017","unstructured":"Khemani D, Eckert D, O\u2019Neil J, et al. Effect of liraglutide on gastric emptying at 5 and 16 weeks: a single-center, randomized, placebo-controlled trial in 32 patients. Gastroenterology. 2017;152(5):S83.","journal-title":"Gastroenterology"},{"issue":"7","key":"3249_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2337\/dc14-1984","volume":"38","author":"JJ Meier","year":"2015","unstructured":"Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263\u201373.","journal-title":"Diabetes Care"},{"issue":"6","key":"3249_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/dom.12247","volume":"16","author":"Y Nagai","year":"2014","unstructured":"Nagai Y, Hashimoto E, Oikawa R, et al. Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2014;16(6):573\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"3249_CR14","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1007\/s00464-014-3990-z","volume":"29","author":"Z Sun","year":"2015","unstructured":"Sun Z, Rodriguez J, Mcmichael J, et al. Surgical treatment of medically refractory gastroparesis in the morbidly obese. Surg Endosc. 2015;29(9):2683\u20139.","journal-title":"Surg Endosc"},{"issue":"5","key":"3249_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.soard.2014.01.013","volume":"10","author":"PK Papasavas","year":"2014","unstructured":"Papasavas PK, Ng JS, Stone AM, et al. Gastric bypass surgery as treatment of recalcitrant gastroparesis. Surg Obes Relat Dis. 2014;10(5):795\u20139.","journal-title":"Surg Obes Relat Dis"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11695-018-3249-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-018-3249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-018-3249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T14:15:23Z","timestamp":1594736123000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11695-018-3249-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["3249"],"URL":"https:\/\/doi.org\/10.1007\/s11695-018-3249-1","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"17 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Dr. Modi has received speaker fees for educational events and honoraria for the development of educational materials from NovoNordisk Canada and Shire Pharma Canada. She has also received speaker fees from Valeant Canada and serves on the advisory board. Dr. Cawsey has received speaker fees and consulting fees from NovoNordisk Canada. Dr. Sharma has received speaker fees and consulting fees from NovoNordisk Canada and Merck.\u00a0 He also serves on the advisory board for Valeant Canada.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}